Alpha Centric Advisors LLC Neurocrine Biosciences Inc Transaction History

Alpha Centric Advisors LLC

  • $97.4 Million
  • Q4 2024

A detailed history of Alpha Centric Advisors LLC transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Alpha Centric Advisors LLC holds 3,684 shares of NBIX stock, worth $459,652. This represents 0.52% of its overall portfolio holdings.

Number of Shares
3,684
Previous 22,500 83.63%
Holding current value
$459,652
Previous $2.59 Million 80.62%
% of portfolio
0.52%
Previous 2.19%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Jan 31, 2025
SELL
$111.62 - $139.44 $2.1 Million - $2.62 Million
-18,816 Reduced 83.63%
3,684 $502,000
Q3 2024

Oct 30, 2024
BUY
$114.58 - $153.15 $1.78 Million - $2.37 Million
15,500 Added 221.43%
22,500 $2.59 Million
Q1 2024

Apr 24, 2024
BUY
$130.4 - $143.74 $912,800 - $1.01 Million
7,000 New
7,000 $965,000
Q3 2023

Nov 13, 2023
SELL
$94.02 - $117.1 $611,130 - $761,150
-6,500 Reduced 17.81%
30,000 $3.38 Million
Q2 2023

Aug 08, 2023
BUY
$89.53 - $104.87 $1.88 Million - $2.2 Million
21,000 Added 135.48%
36,500 $3.44 Million
Q1 2023

May 12, 2023
BUY
$94.11 - $123.02 $1.46 Million - $1.91 Million
15,500 New
15,500 $1.57 Million
Q2 2021

Mar 09, 2022
SELL
$89.43 - $102.27 $178,860 - $204,540
-2,000 Closed
0 $0
Q1 2021

Mar 09, 2022
SELL
$87.57 - $119.4 $70,056 - $95,520
-800 Reduced 28.57%
2,000 $195,000
Q4 2020

Mar 11, 2022
BUY
$86.91 - $108.33 $217,275 - $270,825
2,500 Added 833.33%
2,800 $268,000
Q3 2020

Mar 11, 2022
BUY
$96.16 - $135.15 $7,212 - $10,136
75 Added 33.33%
300 $29,000
Q2 2020

Mar 11, 2022
BUY
$85.09 - $130.36 $19,145 - $29,331
225 New
225 $27,000

Others Institutions Holding NBIX

# of Institutions
649
Shares Held
97.1M
Call Options Held
749K
Put Options Held
553K
View Full List

About NEUROCRINE BIOSCIENCES INC

NBIX Quotes by TradingView
  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $11.9B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track Alpha Centric Advisors LLC Portfolio

Follow Alpha Centric Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Alpha Centric Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Alpha Centric Advisors LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email